The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
暂无分享,去创建一个
B. Ebert | J. Griffin | D. Frank | S. R. Walker | E. Nelson | E. Weisberg | M. Bar‐Natan | R. Barrett | L. Gashin | Shariya Terrell | Josephine L. Klitgaard | L. Santo | Martha Addorio | Sarah R Walker | S. Walker | Laurie B. Gashin
[1] D. Tenen,et al. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. , 2010, Blood.
[2] L. Hennighausen,et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia , 2010, EMBO molecular medicine.
[3] W. Tse,et al. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. , 2009, Blood.
[4] T. Pringsheim,et al. Pimozide for tics in Tourette's syndrome. , 2009, The Cochrane database of systematic reviews.
[5] K. Glaser,et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. , 2007, Blood.
[6] D. Chauhan,et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. , 2008, Blood.
[7] B. Quesnel,et al. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism , 2008, Leukemia.
[8] Charles P. Lin,et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. , 2007, Blood.
[9] Bodo Grimbacher,et al. STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.
[10] D. Frank. STAT3 as a central mediator of neoplastic cellular transformation. , 2007, Cancer letters.
[11] A. Kimura,et al. Establishment and characterization of a novel imatinib‐sensitive chronic myeloid leukemia cell line MYL, and an imatinib‐resistant subline MYL‐R showing overexpression of Lyn , 2007, European journal of haematology.
[12] D. Frank,et al. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas , 2007, Oncogene.
[13] B. Druker,et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. , 2006, Blood.
[14] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[15] R. Ilaria,et al. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. , 2006, Blood.
[16] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[17] J. Melo,et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry , 2006, Leukemia.
[18] A. Ganser,et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). , 2006, Blood.
[19] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[20] Wolfgang Hiddemann,et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). , 2005, Blood.
[21] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[22] C. Deng,et al. Inactivation of Stat5 in Mouse Mammary Epithelium during Pregnancy Reveals Distinct Functions in Cell Proliferation, Survival, and Differentiation , 2004, Molecular and Cellular Biology.
[23] Matthew B. Wilson,et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.
[24] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[25] K. Antman,et al. Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.
[26] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.
[27] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[28] J. Griffin,et al. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.
[29] A. Miyajima,et al. Constitutive Activation of STAT5 by a Point Mutation in the SH2 Domain* , 2000, The Journal of Biological Chemistry.
[30] A. Yoshimura,et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. , 1997, Blood.
[31] R. V. van Etten,et al. P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.
[32] L. Varticovski,et al. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. , 1996, Leukemia.
[33] C. Sawyers,et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.
[34] J. Griffin,et al. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.